These might include: Blood tests to assess for coeliac disease, inflammatory markers, or thyroid function Breath tests for lactose intolerance or small intestinal bacterial overgrowth Abdominal imaging (ultrasound or CT) if structural abnormalities are suspected Faecal calprotectin if inflammatory bowel disease is a concern Referral to gastroenterology for specialist assessment if symptoms persist despite initial management The MHRA's Yellow Card scheme allows patients and healthcare professionals to report suspected side effects of medications, including GLP-1 agonists
Recent studies found beneficial effects on heart failure with preserved ejection fraction and on metabolic dysfunctionassociated steatohepatitis
Its typically used for blood sugar regulation, especially in those with insulin resistance or prediabetes, but some women also notice a bit of weight loss, too
Obesity should be managed by reduced caloric intake, but dietary management for this should also take into account the nature of the feces
B.PallejaA.WismannP.FabriciusK.RigboltK.et al (2019)
After 68 weeks, mean weight change was approximately 14.9% with semaglutide compared with 2.4% with placebo
